Skip to content

Home
Docs
Parameter
Laboratory Tests
Factor IX (Chromogenic)

Analytical Information

A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay
Analytical performance specifications for hemostasis parameters
Assuring quality in the postanalytical phase
Comparison of two statistical software programs for determining reference intervals of screening coagulation assays
Critical pre-examination variables in hemostasis testing
Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine
Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
Lupus anticoagulant testing: analyzing fresh samples after a single centrifugation and after a 6-8 hr delay
Minimum citrate tube fill volume for routine coagulation testing
Pre-Analytical Issues in Platelet Function Testing – An Update
Pre-Analytical Issues in Platelet Function Testing – An Update
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
Risk management for laboratory testing
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
The use of quality indicators for the pre-analytical phase
Update on platelet aggregation testing

Assays

Clotting factor (II, V, VII and X)
Clotting factor (VIII, IX, XI and XII)
Factor VIII Inhibitor
- Factor VIII deficient plasma
- Normal pooled plasma
Factor XIII
- Factor XIII activity
- Factor XIII antigen
Fibrinolysis
Heparin Induced Thrombocytopenia
- Immunological test
Homocysteine
- Method
Screening
Thrombophilia
Von Willebrand Factor

Cases

A patient with acquired factor X deficiency and metastatic carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumours?
A patient with mild haemophilia A
A severe haemophilia A patient treated with emicizumab, case study
Acquired factor X deficiency
Acquired Glanzmann’s thrombasthenia
Acquired haemophilia A
Acquired Hemophilia A, case study
Acquired protein S deficiency with purpura fulminans presentation in the aftermath of varicella zoster in a child
Acquired von Willebrand disease and marginal zone lymphoma
Diagnosis of a previously unnoticed factor XIII deficiency after ovarian haemorrhage in a 13-year-old girl with extradural haematoma and defective wound healing in her medical history
Dysfibrinogenemia, case study
Effect of high haematocrit levels on coagulation testing
Factor V Inhibitor
Haemophilia A and treatment, case study
Haemophilia B and treatment, case study
Hermansky Pudlak syndrome
Hermansky-Pudlak syndrome
How to monitor Haemophilia A patients switching from one therapy to another
Isolated acquired factor VII deficiency: Report of Two Cases and Review of the Literature
Lupus Anticoagulant-Hypoprothrombinemia Syndrome
Phenotypical change of the activated protein C resistance ratio after liver transplantation
Prekallikrein deficiency
Trauma-Induced Coagulopathy, case study
Two cases of autosomal dominant macrothrombocytopenia caused by a rare GPIBB variant
Von Willebrand Disease type 1, case study
Von Willebrand Disease type 2B, case study
Von Willebrand Jürgens syndrome type I, case study 2016
Von Willebrand Jürgens syndrome type I, case study 2019

ECAT Documentation

Meetings
- Meeting
- Webinars
Publications
- 1. Publication list ECAT Foundation
Special Issue

Guidelines

Diagnosis and classification of factor XIII deficiencies, SSC recommendation
Field Study Evaluating Optimal Interpretation Methods for Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies (ICSH)
Guidance for INR and D-dimer testing using point of care testing in primary care, ICSH recommendations
Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls, ICSH recommendations
ICSH Recommendations for Hemostasis Critical Values, Tests, and Reporting
ICSH Recommendations for laboratory measurement of ADAMTS13
ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
ICSH recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests
Laboratory guidance for the evaluation of haemostasis analyser-reagent test systems. Part 1: Instrument-specific issues and commonly used coagulation screening tests. ICSH Recommendations
Laboratory guidance for the verification of haemostasis analyser-reagent test systems. Part 2: Specialist tests and calibrated assays, ICSH recommendations
Recommendations for collection of blood samples for coagulation testing, ICSH recommendations
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Recommendations for processing of blood samples for coagulation testing, ICSH recommendations
Recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders, ICSH recommendations
Thrombin generation measurement in haemophilia, SSC recommendation
Update Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, ICSH recommendations

Haemostatic Cascade

Activation of Platelets by Thrombin
Activation of Protein C by Thrombin
Activation of TAFI by Thrombin
Amino Acid structure of Natural Hirudin
Coagulation Pathways (All Components)
Fibrinolytic Pathway
Intrinsic Pathway APTT
Nucleotide sequences of RNA Codons Encoding for Amino Acids
TF Pathway (Extrinsic) with Common Pathway (PT)

Parameter

Laboratory Tests
Test Information

Quality Issues

A systematic approach for handling unacceptable EQA results
Algorithm A, a new statistical approach for the evaluation of survey results
An approach for estimating measurement uncertainty in medical laboratories using data from long-term quality control and external quality assessment schemes
Assuring quality in the postanalytical phase
Bayesian strategy in long-term IQC results management: practical interest and compliance with standards
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
Bivariate Z-score Analysis
Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine
Does quality matter?
External quality assessment / proficiency testing for platelet function disorders
External quality assessment for Factor VIII and Factor IX
External quality assessment for Factor XIII
External quality assessment for immunological Heparin-Induced Thrombocytopenia testing
External quality assessment for Rivaroxaban and Dabigatran
External quality assessment for von Willebrand Factor laboratory analysis
External Quality Assessment in haemostasis
External quality control for CoaguChek XS INR monitors
Harmonizing light transmission aggregometry in the Netherlands by implementation of the SSC-ISTH guideline
How to establish the mean and standard deviation of internal quality control samples to construct control charts.
How to interpret the Z-score in relation to the homogeneity of the sample used in a survey
Internal Quality Control for Coagulation: Repeating the same mistakes as chemistry? Or leaping ahead into the 21st century?
Interpretation of the Z-score
Long-term evaluation of EQA results
Quality Assurance of replacement therapy and future perspectives
Quality control in the haemostasis laboratory
Results of the surveys for heparin monitoring
Risk management for laboratory testing
The between-laboratoy variation of Factor VIII inhibitor testing
The measurement of low Factor XIII activity with the Siemens Berichrom method
The relevance of accreditation for medical laboratories: An added value for patient care
The use of quality indicators for the pre-analytical phase
Validation of methods in hemostasis testing: a practical approach
Wet Workshop on Platelet Function Testing

Surveys and Studies

A severe haemophilia A patient treated with emicizumab, case study
Acquired Hemophilia A, case study
Dysfibrinogenemia, case study
Emicizumab pilot study, part I
Emicizumab pilot study, part II
External quality assessment for Factor VIII and Factor IX
External quality assessment for Factor XIII
External quality assessment for immunological Heparin-Induced Thrombocytopenia testing
External quality assessment for Rivaroxaban and Dabigatran
External quality assessment for von Willebrand Factor laboratory analysis
External Quality Control for PFA 100/200
Fibrin(ogen) Degradation Products Pilot Study
Functional Heparin-Induced Thrombocytopenia Pilot Study
Haemophilia A and treatment, case study
Haemophilia B and treatment, case study
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Pilot Study on Bivalirudin
Pilot Study on Contact Factor testing
Pilot Study on Light Transmission Aggregation
Platelet Light Transmission Aggregation Pilot Study
Pre- and Post-analytical Survey 2021
Pre- and Post-analytical Survey 2022
Pre- and Post-analytical Survey 2023
Results of samples spiked with chimeric monoclonal anti-PF4 antibody 1C12 in ECAT external quality assessment surveys for heparin-induced thrombocytopenia (HIT) diagnosis
The between-laboratoy variation of Factor VIII inhibitor testing
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Trauma-Induced Coagulopathy, case study
Von Willebrand Disease type 1, case study
Von Willebrand Disease type 2B, case study
Von Willebrand Jürgens syndrome type I, case study 2016
Von Willebrand Jürgens syndrome type I, case study 2019

Terminology

Terminology

Factor IX (Chromogenic)

Related items

Analytical Information : 3

A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay

The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies

The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys

Cases : 1

Haemophilia B and treatment, case study

ECAT Documents : 27

Intrinsic Pathway of Coagulation

Hemophilia B

Factor IX Concentrates

Factor IX (FIX)

Extrinsic Pathway of Coagulation

Coumarin

Coagulation Factors

Bethesda Inhibitor Assay (Titer)

Performance of factor IX extended half-life product measurements in external quality control assessment programs

The performance of FVIII and FIX measurement in ECAT surveys

Laboratory assays for the measurement of Factor VIII and IX

Gene therapy, the future in hemophilia treatment?

The role of molecular biology in the diagnosis of impaired haemostasis

How to measure low levels of Factor VIII and IX

Introduction on Inhibitor Testing

Haemophilia, new development in patient treatment

Quality Assurance of extended half-life products

Laboratory measurement of extended half-life FIX

Potency labelling of extended half-life FVIII en FIX products

Treatmentof patients with extended half-life FVIII and FIX products

One-stage clotting assay versus chromogenic testing in the diagnosis of haemophilia patients

Haemophilia treatment and laboratory testing

New developments in haemophilia treatment

Hemophilia and gene therapy

When Haemostasis Assays Mislead

Guidance for FVIII/FIX Inhibitor testing

International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors

Guidelines : 1

Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations

Haemostatic Cascade : 6

TF Pathway (Extrinsic) with Common Pathway (PT)

Intrinsic Pathway APTT

Coagulation Pathways (All Components)

Activation of TAFI by Thrombin

Activation of Protein C by Thrombin

Activation of Platelets by Thrombin

Quality Issues : 3

Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications

Quality Assurance of replacement therapy and future perspectives

External quality assessment for Factor VIII and Factor IX

Surveys and Studies : 3

Emicizumab pilot study, part II

Emicizumab pilot study, part I

Performance of factor IX extended half-life product measurements in external quality control assessment programs

Clotpedia

© 2022 ECAT Clotpedia All Rights Reserved

ECAT Foundation
P.O. Box 107
2250 AC Voorschoten | The Netherlands
Email: info@ecat.nl
T: +31 (0) 71 3030 910 | F: +31 (0) 71 3030 919

Disclaimer
ECAT collaborates with the website Practical-Hemostasis.com. Ecat is not responsible for the content of this website.
Clotpedia includes content of the former website Clot-ed.com (owned by Marlies Ledford-Kraemer)

Clotpedia Support Form

Success

Thank you for submitting your message